Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

1/2 Clinical Coordinating Center for the Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction Study (SPIRRIT-EX)

Award Number: UH3HL173571
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/05/2024
PERIOD OF PERFORMANCE END DATE: 05/31/2028

Group Awards By:

View Award Description

1/2 Clinical Coordinating Center for the Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction Study (SPIRRIT-EX) - Project Summary: Over half of the 6.7 million adults with heart failure in the United States have a normal or near-normal left ventricular ejection fraction, or heart failure with preserved ejection fraction (HFpEF). The prevalence of HFpEF is increasing over time, due to ageing of the population and other factors. Morbidity and mortality for patients with HFpEF remains high; rates are similar to those observed in HF with reduced ejection fraction. Poor outcomes in HFpEF are related to a lack of evidence-based therapeutic options. There is an urgent need to efficiently conduct large, simple, streamlined trials with clinically relevant endpoints comprised of therapeutic interventions for HFpEF patients. Mineralocorticoid receptor antagonists (including spironolactone) present one promising treatment for HFpEF. In clinical trials of participants with HF with reduced ejection fraction, mineralocorticoid receptor antagonists have consistently demonstrated their ability to improve symptoms, and reduce mortality and hospitalizations. However, the TOPCAT trial was the largest study of mineralocorticoid receptor antagonists in HFpEF. In TOPCAT, spironolactone did not significantly reduce the primary outcome (a composite of cardiovascular death, aborted cardiac arrest, or hospitalization for HF) relative to placebo, but did reduce a secondary endpoint of HF hospitalization (HR 0.83, 95% CI 0.69–0.99, p=0.04). A post-hoc regional analysis of TOPCAT, limited to North and South America, found that spironolactone reduced the primary endpoint (HR 0.82, 95% CI 0.69–0.98) compared to placebo. Therefore, TOPCAT demonstrated the potential promise of mineralocorticoid receptor antagonists in HFpEF but was not definitive. The SPIRRIT-HFpEF (Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction) randomized clinical trial was funded in 2018 for 5 years and has now randomized >1900 participants. The primary aim of SPIRRIT-HFpEF is to test the hypothesis that use of spironolactone will reduce total HF events (total hospitalizations for HF and death from cardiovascular causes). SPIRRIT-HFpEF will complete enrollment December 31, 2023. The current application for SPIRRIT-EX is for a free-standing extension of the SPIRRIT-HFpEF trial to extend follow-up through 2025 and to allow for accrual of additional clinical events. The application will specifically support extended follow-up, secondary analyses (including a pre-specified meta-analysis of data from another ongoing HFpEF clinical trial), dissemination of results, and closeout activities of participants previously randomized in SPIRRIT-HFpEF. Resolving whether spironolactone is beneficial in patients with HFpEF would have tremendous public health implications.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $435,508 )
2026	2026	DUKE UNIVERSITY	2200 W MAIN ST	DURHAM	NC	27705	DURHAM	USA	Cardiovascular Diseases Research	001	3	6/12/2026	SUPPLEMENT FOR EXPANSION	$413,146
2026	2026	DUKE UNIVERSITY	2200 W MAIN ST	DURHAM	NC	27705	DURHAM	USA	Cardiovascular Diseases Research	000	3	6/1/2026	NON-COMPETING CONTINUATION	$22,362
														Subtotal = $435,508

Issue Date FY: 2025 ( Subtotal = $830,844 )
2025	2025	DUKE UNIVERSITY	2200 W MAIN ST	DURHAM	NC	27705	DURHAM	USA	Cardiovascular Diseases Research	001	2	8/8/2025	SUPPLEMENT FOR EXPANSION	$332,946
2025	2025	DUKE UNIVERSITY	2200 W MAIN ST	DURHAM	NC	27705	DURHAM	USA	Cardiovascular Diseases Research	000	2	8/6/2025	EXTENSION WITH OR WITHOUT FUNDS	$497,898
														Subtotal = $830,844

Grand Total All Awards = $1,266,352

Top

All Categories

About

Search

Reports

Data Submission

Award Information

1/2 Clinical Coordinating Center for the Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction Study (SPIRRIT-EX)

Award Number: UH3HL173571

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/05/2024

PERIOD OF PERFORMANCE END DATE: 05/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer